What intravenous dose of bumetanide (Bumex) is equivalent to 4 mg oral administration?

Bumetanide 4 mg Oral to IV Conversion

For patients already taking bumetanide 4 mg orally, convert to 4-10 mg IV daily when transitioning to intravenous therapy, typically starting at 4 mg IV and titrating based on response.

Conversion Rationale

The 2019 ACC Expert Consensus Decision Pathway provides the most authoritative guidance on bumetanide dosing conversion 1. The guideline explicitly states that for patients receiving loop diuretics prior to admission, the oral dose should be changed to an intravenous dose of 1-2.5 times the home dose 1. This means:

• 4 mg oral bumetanide = 4-10 mg IV bumetanide
• Start at the lower end (4 mg IV) for stable patients
• Use higher conversion ratios (up to 10 mg IV) for patients with significant fluid overload or diuretic resistance

Bioavailability Considerations

The conversion range accounts for bumetanide's high but variable oral bioavailability:

• Oral bioavailability is approximately 80-81% in both healthy subjects and heart failure patients 2, 3, 4
• Unlike furosemide (which has ~40% bioavailability and requires 2:1 IV:oral conversion), bumetanide's superior bioavailability means the IV dose can be closer to the oral dose 4
• However, in acute decompensated heart failure, intestinal edema can reduce oral absorption unpredictably, justifying the higher conversion ratios 5

Practical Dosing Algorithm

Initial IV Conversion:

1. Standard conversion: 4 mg oral → 4 mg IV once to three times daily 1
2. For significant congestion: 4 mg oral → 6-8 mg IV once to three times daily
3. For diuretic resistance: 4 mg oral → 10 mg IV (maximum single dose per guidelines) 1

Alternative: Continuous Infusion

• Load with 1 mg IV, then 0.5-2 mg/hour continuous infusion 1
• Maximum infusion rate: 4 mg/hour 1

Monitoring and Titration

Assess diuretic response at 2 hours post-dose 5:

• Spot urine sodium <50-70 mEq/L indicates inadequate response
• Hourly urine output <100-150 mL during first 6 hours suggests need for dose escalation
• Adjust dose every 2-3 days based on volume status, daily weights, and renal function 6

Important Caveats

Maximum dosing limits 1:

• Single IV dose: 5 mg (per ACC guidelines)
• Daily maximum: 10 mg/day
• Continuous infusion maximum: 4 mg/hour

Safety considerations:

• Monitor electrolytes (potassium, magnesium) daily during IV therapy 1
• Expect modest creatinine elevation during effective decongestion (typically returns to baseline post-discharge) 1
• Reduce dose if hypotension or significant azotemia develops without signs of fluid retention 7

Transition back to oral: Once adequate decongestion achieved, transition to oral bumetanide at approximately the same total daily dose as IV, given the high bioavailability 2, 3.